Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) were down 5.2% during mid-day trading on Friday . The company traded as low as $65.39 and last traded at $64.70. Approximately 1,744,583 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 2,674,893 shares. The stock had previously closed at $68.27.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on HOLX shares. Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday. UBS Group increased their target price on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. Argus raised their price objective on shares of Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a report on Friday. Morgan Stanley raised their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $79.38.
Check Out Our Latest Stock Analysis on HOLX
Hologic Price Performance
The business's 50-day simple moving average is $66.46 and its 200-day simple moving average is $62.72. The stock has a market cap of $14.61 billion, a PE ratio of 27.34, a PEG ratio of 2.47 and a beta of 0.57. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.
Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.
Institutional Investors Weigh In On Hologic
Large investors have recently modified their holdings of the stock. Chung Wu Investment Group LLC bought a new stake in Hologic during the second quarter worth about $26,000. Caitong International Asset Management Co. Ltd boosted its stake in Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 273 shares in the last quarter. Loomis Sayles & Co. L P bought a new stake in Hologic during the second quarter worth about $33,000. Zions Bancorporation National Association UT bought a new stake in Hologic during the first quarter worth about $34,000. Finally, Cromwell Holdings LLC boosted its stake in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock worth $38,000 after acquiring an additional 436 shares in the last quarter. Institutional investors own 94.73% of the company's stock.
Hologic Company Profile
(
Get Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
